Global Combination Vaccine and Multivalent Vaccine Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11241107

Publication Date:

November 18, 2024

Pages:

158

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Combination Vaccine and Multivalent Vaccine market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淐ombination Vaccine and Multivalent Vaccine Industry Forecast鈥� looks at past sales and reviews total world Combination Vaccine and Multivalent Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Combination Vaccine and Multivalent Vaccine sales for 2023 through 2029. With Combination Vaccine and Multivalent Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Combination Vaccine and Multivalent Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Combination Vaccine and Multivalent Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Combination Vaccine and Multivalent Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Combination Vaccine and Multivalent Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Combination Vaccine and Multivalent Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Combination Vaccine and Multivalent Vaccine.
United States market for Combination Vaccine and Multivalent Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Combination Vaccine and Multivalent Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Combination Vaccine and Multivalent Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Combination Vaccine and Multivalent Vaccine players cover Merck & Co., Pfizer, Sanofi Pasteur, GlaxoSmithKline, BioNTech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Combination Vaccine and Multivalent Vaccine market by product type, application, key players and key regions and countries.
Segmentation by Type:
Combination Vaccine
Multivalent Vaccine
Segmentation by Application:
Hospital
Centers for Disease Control and Prevention
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Combination Vaccine
Multivalent Vaccine
Segmentation by Application:
Hospital
Centers for Disease Control and Prevention
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck & Co.
Pfizer
Sanofi Pasteur
GlaxoSmithKline
BioNTech
Moderna
Dynavax
Novavax
Sino Biopharm
Kangtai Bio
Zhifei Biological
Walvax
Minhai Biological
Sinovac
Wantai Biological
Wanbangde Pharmaceutical
AIM Bio
Antejin Biotechnology
Lanzhou Institute of Biological Products
Wuhan Institute of Biological Products
Beijing Institute of Biological Products
Chengdu Institute of Biological Products

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Combination Vaccine and Multivalent Vaccine Market Size 2019-2030
2.1.2 Combination Vaccine and Multivalent Vaccine Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Combination Vaccine and Multivalent Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Combination Vaccine and Multivalent Vaccine Segment by Type
2.2.1 Combination Vaccine
2.2.2 Multivalent Vaccine
2.3 Combination Vaccine and Multivalent Vaccine Market Size by Type
2.3.1 Combination Vaccine and Multivalent Vaccine Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Combination Vaccine and Multivalent Vaccine Market Size Market Share by Type (2019-2024)
2.4 Combination Vaccine and Multivalent Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Centers for Disease Control and Prevention
2.4.3 Others
2.5 Combination Vaccine and Multivalent Vaccine Market Size by Application
2.5.1 Combination Vaccine and Multivalent Vaccine Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Combination Vaccine and Multivalent Vaccine Market Size Market Share by Application (2019-2024)
3 Combination Vaccine and Multivalent Vaccine Market Size by Player
3.1 Combination Vaccine and Multivalent Vaccine Market Size Market Share by Player
3.1.1 Global Combination Vaccine and Multivalent Vaccine Revenue by Player (2019-2024)
3.1.2 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Player (2019-2024)
3.2 Global Combination Vaccine and Multivalent Vaccine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Combination Vaccine and Multivalent Vaccine by Region
4.1 Combination Vaccine and Multivalent Vaccine Market Size by Region (2019-2024)
4.2 Global Combination Vaccine and Multivalent Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Combination Vaccine and Multivalent Vaccine Market Size Growth (2019-2024)
4.4 APAC Combination Vaccine and Multivalent Vaccine Market Size Growth (2019-2024)
4.5 Europe Combination Vaccine and Multivalent Vaccine Market Size Growth (2019-2024)
4.6 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Growth (2019-2024)
5 Americas
5.1 Americas Combination Vaccine and Multivalent Vaccine Market Size by Country (2019-2024)
5.2 Americas Combination Vaccine and Multivalent Vaccine Market Size by Type (2019-2024)
5.3 Americas Combination Vaccine and Multivalent Vaccine Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Combination Vaccine and Multivalent Vaccine Market Size by Region (2019-2024)
6.2 APAC Combination Vaccine and Multivalent Vaccine Market Size by Type (2019-2024)
6.3 APAC Combination Vaccine and Multivalent Vaccine Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2019-2024)
7.2 Europe Combination Vaccine and Multivalent Vaccine Market Size by Type (2019-2024)
7.3 Europe Combination Vaccine and Multivalent Vaccine Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine by Region (2019-2024)
8.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Type (2019-2024)
8.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Combination Vaccine and Multivalent Vaccine Market Forecast
10.1 Global Combination Vaccine and Multivalent Vaccine Forecast by Region (2025-2030)
10.1.1 Global Combination Vaccine and Multivalent Vaccine Forecast by Region (2025-2030)
10.1.2 Americas Combination Vaccine and Multivalent Vaccine Forecast
10.1.3 APAC Combination Vaccine and Multivalent Vaccine Forecast
10.1.4 Europe Combination Vaccine and Multivalent Vaccine Forecast
10.1.5 Middle East & Africa Combination Vaccine and Multivalent Vaccine Forecast
10.2 Americas Combination Vaccine and Multivalent Vaccine Forecast by Country (2025-2030)
10.2.1 United States Market Combination Vaccine and Multivalent Vaccine Forecast
10.2.2 Canada Market Combination Vaccine and Multivalent Vaccine Forecast
10.2.3 Mexico Market Combination Vaccine and Multivalent Vaccine Forecast
10.2.4 Brazil Market Combination Vaccine and Multivalent Vaccine Forecast
10.3 APAC Combination Vaccine and Multivalent Vaccine Forecast by Region (2025-2030)
10.3.1 China Combination Vaccine and Multivalent Vaccine Market Forecast
10.3.2 Japan Market Combination Vaccine and Multivalent Vaccine Forecast
10.3.3 Korea Market Combination Vaccine and Multivalent Vaccine Forecast
10.3.4 Southeast Asia Market Combination Vaccine and Multivalent Vaccine Forecast
10.3.5 India Market Combination Vaccine and Multivalent Vaccine Forecast
10.3.6 Australia Market Combination Vaccine and Multivalent Vaccine Forecast
10.4 Europe Combination Vaccine and Multivalent Vaccine Forecast by Country (2025-2030)
10.4.1 Germany Market Combination Vaccine and Multivalent Vaccine Forecast
10.4.2 France Market Combination Vaccine and Multivalent Vaccine Forecast
10.4.3 UK Market Combination Vaccine and Multivalent Vaccine Forecast
10.4.4 Italy Market Combination Vaccine and Multivalent Vaccine Forecast
10.4.5 Russia Market Combination Vaccine and Multivalent Vaccine Forecast
10.5 Middle East & Africa Combination Vaccine and Multivalent Vaccine Forecast by Region (2025-2030)
10.5.1 Egypt Market Combination Vaccine and Multivalent Vaccine Forecast
10.5.2 South Africa Market Combination Vaccine and Multivalent Vaccine Forecast
10.5.3 Israel Market Combination Vaccine and Multivalent Vaccine Forecast
10.5.4 Turkey Market Combination Vaccine and Multivalent Vaccine Forecast
10.6 Global Combination Vaccine and Multivalent Vaccine Forecast by Type (2025-2030)
10.7 Global Combination Vaccine and Multivalent Vaccine Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Combination Vaccine and Multivalent Vaccine Forecast
11 Key Players Analysis
11.1 Merck & Co.
11.1.1 Merck & Co. Company Information
11.1.2 Merck & Co. Combination Vaccine and Multivalent Vaccine Product Offered
11.1.3 Merck & Co. Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Merck & Co. Main Business Overview
11.1.5 Merck & Co. Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Combination Vaccine and Multivalent Vaccine Product Offered
11.2.3 Pfizer Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Company Information
11.3.2 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Offered
11.3.3 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Sanofi Pasteur Main Business Overview
11.3.5 Sanofi Pasteur Latest Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Information
11.4.2 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Offered
11.4.3 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline Main Business Overview
11.4.5 GlaxoSmithKline Latest Developments
11.5 BioNTech
11.5.1 BioNTech Company Information
11.5.2 BioNTech Combination Vaccine and Multivalent Vaccine Product Offered
11.5.3 BioNTech Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 BioNTech Main Business Overview
11.5.5 BioNTech Latest Developments
11.6 Moderna
11.6.1 Moderna Company Information
11.6.2 Moderna Combination Vaccine and Multivalent Vaccine Product Offered
11.6.3 Moderna Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Moderna Main Business Overview
11.6.5 Moderna Latest Developments
11.7 Dynavax
11.7.1 Dynavax Company Information
11.7.2 Dynavax Combination Vaccine and Multivalent Vaccine Product Offered
11.7.3 Dynavax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Dynavax Main Business Overview
11.7.5 Dynavax Latest Developments
11.8 Novavax
11.8.1 Novavax Company Information
11.8.2 Novavax Combination Vaccine and Multivalent Vaccine Product Offered
11.8.3 Novavax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Novavax Main Business Overview
11.8.5 Novavax Latest Developments
11.9 Sino Biopharm
11.9.1 Sino Biopharm Company Information
11.9.2 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Offered
11.9.3 Sino Biopharm Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sino Biopharm Main Business Overview
11.9.5 Sino Biopharm Latest Developments
11.10 Kangtai Bio
11.10.1 Kangtai Bio Company Information
11.10.2 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Offered
11.10.3 Kangtai Bio Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Kangtai Bio Main Business Overview
11.10.5 Kangtai Bio Latest Developments
11.11 Zhifei Biological
11.11.1 Zhifei Biological Company Information
11.11.2 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Offered
11.11.3 Zhifei Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Zhifei Biological Main Business Overview
11.11.5 Zhifei Biological Latest Developments
11.12 Walvax
11.12.1 Walvax Company Information
11.12.2 Walvax Combination Vaccine and Multivalent Vaccine Product Offered
11.12.3 Walvax Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Walvax Main Business Overview
11.12.5 Walvax Latest Developments
11.13 Minhai Biological
11.13.1 Minhai Biological Company Information
11.13.2 Minhai Biological Combination Vaccine and Multivalent Vaccine Product Offered
11.13.3 Minhai Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Minhai Biological Main Business Overview
11.13.5 Minhai Biological Latest Developments
11.14 Sinovac
11.14.1 Sinovac Company Information
11.14.2 Sinovac Combination Vaccine and Multivalent Vaccine Product Offered
11.14.3 Sinovac Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Sinovac Main Business Overview
11.14.5 Sinovac Latest Developments
11.15 Wantai Biological
11.15.1 Wantai Biological Company Information
11.15.2 Wantai Biological Combination Vaccine and Multivalent Vaccine Product Offered
11.15.3 Wantai Biological Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Wantai Biological Main Business Overview
11.15.5 Wantai Biological Latest Developments
11.16 Wanbangde Pharmaceutical
11.16.1 Wanbangde Pharmaceutical Company Information
11.16.2 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Offered
11.16.3 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Wanbangde Pharmaceutical Main Business Overview
11.16.5 Wanbangde Pharmaceutical Latest Developments
11.17 AIM Bio
11.17.1 AIM Bio Company Information
11.17.2 AIM Bio Combination Vaccine and Multivalent Vaccine Product Offered
11.17.3 AIM Bio Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 AIM Bio Main Business Overview
11.17.5 AIM Bio Latest Developments
11.18 Antejin Biotechnology
11.18.1 Antejin Biotechnology Company Information
11.18.2 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Offered
11.18.3 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Antejin Biotechnology Main Business Overview
11.18.5 Antejin Biotechnology Latest Developments
11.19 Lanzhou Institute of Biological Products
11.19.1 Lanzhou Institute of Biological Products Company Information
11.19.2 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered
11.19.3 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Lanzhou Institute of Biological Products Main Business Overview
11.19.5 Lanzhou Institute of Biological Products Latest Developments
11.20 Wuhan Institute of Biological Products
11.20.1 Wuhan Institute of Biological Products Company Information
11.20.2 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered
11.20.3 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Wuhan Institute of Biological Products Main Business Overview
11.20.5 Wuhan Institute of Biological Products Latest Developments
11.21 Beijing Institute of Biological Products
11.21.1 Beijing Institute of Biological Products Company Information
11.21.2 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered
11.21.3 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Beijing Institute of Biological Products Main Business Overview
11.21.5 Beijing Institute of Biological Products Latest Developments
11.22 Chengdu Institute of Biological Products
11.22.1 Chengdu Institute of Biological Products Company Information
11.22.2 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Offered
11.22.3 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 Chengdu Institute of Biological Products Main Business Overview
11.22.5 Chengdu Institute of Biological Products Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂